Skip to content
Open access

Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL.

Nov 2026 · Genes · 0 citations

Abstract

Objectives: Genome-wide association studies (GWAS) have identified over 212 asthma susceptibility loci, yet the effector genes and the immune cell subsets remain largely unresolved, because conventional prioritization relies on bulk-tissue expression quantitative trait loci (eQTL) that cannot resolve cellular heterogeneity. We aimed to build a cell-type-resolved map of candidate causal genes and prioritize druggable asthma targets. Methods: We integrated single-cell cis-eQTL across 20 peripheral-blood immune subsets from OneK1K with a European-ancestry asthma GWAS meta-analysis from the Global Biobank Meta-analysis Initiative (121,940 cases, 1,254,131 controls), using summary-data-based Mendelian randomization (SMR) with heterogeneity in dependent instrument (HEIDI) filtering followed by Bayesian colocalization, and annotated dual-evidence genes for tractability with the Open Targets Platform. Results: Across 12,754 gene–cell-subset tests, 437 associations were significant (false discovery rate < 0.05, HEIDI pass), implicating 202 genes. Colocalization supported 102 associations across 46 dual-evidence genes. At 17q21, ORMDL3 colocalized in B cells and GSDMB in natural killer, CD8+ effector-memory T and naive B cells. The IL18R1 signal (2q12) did not colocalize, consistent with linkage disequilibrium. In independent eQTL data, 18 of the 46 replicated in at least one pre-specified endpoint, including 10 in whole blood against one of 202 control genes, while the other 28 remain candidates. Twenty-three of the 46 carried tractability evidence, three at a clinical stage. Conclusions: Single-cell eQTL-based Mendelian randomization refines understanding of asthma genetic architecture and delivers a cell-type-anchored shortlist of candidate therapeutic targets. This two-pillar, cell-type-resolved framework yields testable mechanistic insights and supports translational development of precision therapeutic strategies for asthma.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.